Full View

Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment

F Weidemann, M Niemann, F Breunig, S Herrmann… - Circulation, 2009 - Am Heart Assoc
Background—Enzyme replacement therapy with recombinant α-galactosidase A reduces left
ventricular hypertrophy and improves regional myocardial function in patients with Fabry …
被引用次数：576 相关文章

[引用][C] Long-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy: Evidence for a Better Outcome With Early Treatment

F WEIDEMANN, M NIEMANN… - … (New York, NY), 2009 - pascal-francis.inist.fr
Long-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy : Evidence
for a Better Outcome With Early Treatment CNRS Inist Pascal-Francis CNRS Pascal and …
[PDF] archive.org

[PDF][PDF] Long-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy

F Weidemann, M Niemann, F Breunig, S Herrmann… - 2009 - scholar.archive.org
Background—Enzyme replacement therapy with recombinant-galactosidase A reduces left
ventricular hypertrophy and improves regional myocardial function in patients with Fabry …

Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment

F Weidemann, M Niemann, F Breunig… - …, 2009 - pubmed.ncbi.nlm.nih.gov
Background Enzyme replacement therapy with recombinant alpha-galactosidase A reduces
left ventricular hypertrophy and improves regional myocardial function in patients with Fabry …

Long-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy

F Weidemann, M Niemann, F Breunig, S Herrmann… - Circulation, 2009 - cir.nii.ac.jp
抄録< jats: p>< jats: bold>< jats: italic> Background—</jats: italic></jats: bold> Enzyme
replacement therapy with recombinant α-galactosidase A reduces left ventricular …
[PDF] psu.edu

[PDF][PDF] Long-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy

F Weidemann, M Niemann, F Breunig, S Herrmann… - 2009 - Citeseer
Background—Enzyme replacement therapy with recombinant-galactosidase A reduces left
ventricular hypertrophy and improves regional myocardial function in patients with Fabry …

Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.

F Weidemann, M Niemann, F Breunig, S Herrmann… - Circulation, 2009 - europepmc.org
Background Enzyme replacement therapy with recombinant alpha-galactosidase A reduces
left ventricular hypertrophy and improves regional myocardial function in patients with Fabry …
[PDF] academia.edu

[PDF][PDF] Long-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy

F Weidemann, M Niemann, F Breunig, S Herrmann… - 2009 - academia.edu
Background—Enzyme replacement therapy with recombinant-galactosidase A reduces left
ventricular hypertrophy and improves regional myocardial function in patients with Fabry …
[PDF] academia.edu

[PDF][PDF] Long-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy

F Weidemann, M Niemann, F Breunig, S Herrmann… - 2009 - academia.edu
Background—Enzyme replacement therapy with recombinant-galactosidase A reduces left
ventricular hypertrophy and improves regional myocardial function in patients with Fabry …

[引用][C] Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: Evidence for a better outcome with early treatment

F WEIDERMANN - Circulation, 2009 - cir.nii.ac.jp
Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy : Evidence for a
better outcome with early treatment | CiNii Research CiNii 国立情報学研究所 学術情報 …